Banyu, Maruho Receive NHI Approval for Oral Scabies Medication.Tokyo, Japan, Aug 25, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Banyu Pharmaceutical and Maruho Co., Ltd. have announced that an additional indication of Stromectol Tablets 3mg - generic name ivermectin ivermectin an avermectin with broad activity against many helminths and arthropods. A broad-spectrum anthelmintic, acaricide and insecticide, used orally, subcutaneously and as a pour-on. - has been approved for the administration for scabies scabies (skā`bēz), highly contagious parasitic skin disease caused by the itch mite (Sarcoptes scabiei). The disease is also known as itch. treatment under the Nippon Health Insurance (NHI NHI abbr. National Health Insurance ) system, alleviating patients' payment for the drug themselves. Banyu retains approval for the manufacturing and marketing Stromectol in Japan, but has transfered sales rights to Maruho. Stromectol joins with glutamatergic chloride ion channels, increasing the permeability of the cell membrane to chloride ions which kills parasites. Presently, no effective oral drug has been introduced to treat scabies, so the addition of oral drug Stromectol Tablets 3mg has been encouraged by the health sector in Japan. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion